Therapy of inflammatory bowel disease: What to expect in the next decade

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 385-390

  Leiman, David A ^a   Lichtenstein, Gary R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Emerging therapy; Inflammatory bowel disease; Novel treatments

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CHEMOKINE RECEPTOR ANTAGONIST; GOLIMUMAB; HMPL 004; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; JANUS KINASE; JANUS KINASE INHIBITOR; LAQUINIMOD; NATALIZUMAB; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; CCX282-B; MONOCLONAL ANTIBODY; SULFONAMIDE;

CELL ADHESION; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME; TRENDS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MOLECULAR TARGETED THERAPY; NATALIZUMAB; SIGNAL TRANSDUCTION; SULFONAMIDES; TREATMENT OUTCOME; USTEKINUMAB;

EID: 84902264550     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000077     Document Type: Review

References (49)

1. D'Haens G, Deventer SV, Hogenzand RV, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116:1029-1034.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
6. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006; 130:323-333.
7. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007; 56:1232-1239.
8. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132:52-65.
9. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011; 60:780-787.
10. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257-265.
11. Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011; 4:375-389.
12. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146:96-109.
13. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
14. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.
15. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial. Gastroenterology 2007; 132:1672-1683.
16. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699-710.
17. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711-721.
18. Food and Drug Administration. FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. 2013.
19. Takazoe M, Watanabe M, Kawaguchi T, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136:A181.
20. Ajinomoto Pharmaceuticals. PIIa Clinical Study Results of AJM300 in Ulcerative Colitis: Oral a4 integrin inhibitor was demonstrated to be effective in treatment of inflammatory bowel disease for the first time in the world. http:// www.ajinomoto-seiyaku.co.jp/newsrelease/2013/1106e.pdf. [Accessed 2 February 2014]
21. Vermeire S, O'Byrne S, Williams M, Mansfield J. Differentiation between etrolizumab (rhuMAb beta7) and placebo in the Eucalyptus phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to-severely active ulcerative colitis. Gastroenterology 2013; 144:S-36.
22. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547659 in ulcerative colitis: A randomised study. Gut 2011; 60:1068-1075.
23. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-1141.
24. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528.
25. ClinicalTrials.gov: National Institutes of Health, 2014. http://clinicaltrials.gov/ ct2/show/NCT01369342 and http://clinicaltrials.gov/ ct2/show/NCT 01369355. [Accessed 29 January 2014]
26. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:616-624.
27. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335:61-69.
28. Papadakis KA, Prehn J, Moreno ST, et al. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001; 121:246-254.
29. Keshav S, Vanasek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PloS One 2013; 8: e60094.
30. Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 2013; 62:1642-1652.
31. Mayer L, Sandborn WJ, Stepanov Y, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: A phase II randomised study. Gut 2014; 63:442-450.
32. Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014; 13:272-280.
33. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136:1182-1197.
34. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human antiinterleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989-996.
35. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71:1183-1189.
36. Ho RJ, Chien JY. Drug delivery trends in clinical trials and translational medicine: growth in biologic molecule development and impact on rheumatoid arthritis, Crohn's disease, and colitis. J Pharm Sci 2012; 101:2668-2674.
37. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18:985-989.
38. D'Haens GR, Colombel J-F, Sandborn W, et al. 90 safety and efficacy of laquinimod in inducing clinical and biochemical improvement in active Crohn's disease: Results of an exploratory trial. Gastroenterology 2013; 144:S-21.
39. Michelsen KS, Wong MH, Ko B, et al. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bowel Dis 2013; 19:151-164.
40. Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013; 108:90-98.
41. van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol 2013; 29:384-390.
42. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114:433-440.
43. Cassinotti A, Onida F, Annaloro C, et al. P362 autologous haematopoietic stem cell transplantation without CD34þ cell selection for refractory Crohn's disease: The Milan experience after 5 years. J Crohn's Colitis 2012; 6:S153-S154.
44. Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116:6123-6132.
45. Hawkey C, Allez M, Ardizzone S, et al. OC-014 clinical and endoscopic improvement following hematopoietic stem cell transplantation vs mobilisation alone in Crohn's disease. Gut 2013; 62 (Suppl 1):A6.
46. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009; 52:79-86.
47. García-Olmo D, García-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48:1416-1423.
48. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrowderived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60:788-798.
49. Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014; 12:64-71.